Human leukemic B cell activation: functional consequence of membrane IgM interaction with anti-IgM ligand is an alterable cell characteristic.
A functional study of several human malignant B cell populations has indicated that occasional leukemic clones are extraordinarily sensitive to signal transduction through membrane IgM. One isolated hairy cell leukemia (HCL) with low background DNA synthesis was stimulated to significant levels of DNA synthesis when cultured with high (100 micrograms/mL) concentrations of soluble anti-IgM ligands. In contrast to the activation of normal peripheral blood polyclonal B cells, this DNA synthesis was completely independent of accessory T cell factors. Although the HCL clone could also be induced to enter S phase by incubation in media supplemented with only activated T cell supernatant, culture of the clone with activated T cell supernatant plus anti-IgM Ab resulted in DNA synthesis that was significantly less than that induced by either activator alone. Factor(s) in T cell supernatant appear to modulate the leukemic clone so that the binding of ligand to membrane IgM is perceived as an inhibitory rather than a stimulatory signal for DNA synthesis. In terms of Ig Fc independence and low ligand dose requirements, anti-IgM-mediated inhibitory signal transduction in the T cell supernatant-activated HCL clone was found to mimic anti-IgM mediated suppression of the spontaneous DNA synthesis of an alternative HCL clone. The functional results suggest that the type of signal transduced anti-Ig ligands may reflect differences in the activation state of receptive leukemic B cells.
D000888:Antibodies, Anti-Idiotypic / Q000502:physiology; D000951:Antigens, Neoplasm / Q000032:analysis; D000954:Antigens, Surface / Q000032:analysis; D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology / Q000502:physiology*; D002454:Cell Differentiation; D002999:Clone Cells; D004247:DNA / Q000096:biosynthesis; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology / Q000378:metabolism*; D007938:Leukemia / Q000276:immunology / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D008024:Ligands / Q000378:metabolism*; D008213:Lymphocyte Activation; D011947:Receptors, Antigen, B-Cell / Q000235:genetics; D012995:Solubility; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D000888:Antibodies, Anti-Idiotypic; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D007075:Immunoglobulin M; D008024:Ligands; D011947:Receptors, Antigen, B-Cell; D004247:DNA; D013755:Tetradecanoylphorbol Acetate